Partial
Partially Aligned
Patient Risk:
Unknown
Summary
The response accurately reflects label-supported information limited to mechanism/target (C5 complement inhibition) and the absence of any stated cancer indication. However, it makes an additional mechanistic/biological claim about tumor microenvironment effects that is not supported by the provided label excerpts. Safety-critical label elements (e.g., contraindications, dosing/administration, boxed warnings, warnings/precautions, adverse reactions, monitoring, storage) were not provided, so overall label alignment cannot be fully verified.
Category Scores
Accurate Statements
Zilbrysq (zilucoplan) is described as a targeted therapy for complement-mediated disease.
12 CLINICAL PHARMACOLOGY, 12.1 Mechanism of Action (binds C5 and inhibits its cleavage); 12 CLINICAL PHARMACOLOGY, 12.2 Pharmacodynamics (dose dependent inhibition of complement).
The provided information does not specify any cancer indication for Zilbrysq.
1 INDICATIONS AND USAGE (indicated for generalized myasthenia gravis in adult patients who are anti-AChR antibody positive).
Unsupported Statements
Complement activity can influence inflammation and immune responses in the tumor microenvironment.
Not supported by the provided label excerpts; label information provided focuses on complement C5 inhibition and gMG mechanism/effect, not tumor microenvironment immunobiology.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No label-supported dosing/administration, contraindications, boxed warnings, warnings/precautions, adverse reactions, monitoring, storage/handling, or drug interaction information was provided or evaluated, so safety/usage alignment cannot be confirmed beyond the limited excerpts supplied.
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
The response contains no dosing, contraindication, or administration instructions. Safety-critical label elements were not provided, and the only additional claim is an unsupported biological statement about tumor microenvironment effects.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
An unsupported mechanistic statement about tumor microenvironment immunologic effects is included, and safety-critical label alignment cannot be fully assessed due to missing FDA label sections.
Suggested Improvement
Limit claims to label-supported statements from the provided excerpts (e.g., C5 binding/complement inhibition and the labeled gMG indication) and remove the tumor microenvironment claim unless corresponding label text is supplied.